Discovering New Therapeutic Uses for Existing Molecules

Through its Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) program, NCATS aims to improve the process of developing new treatments and cures for disease by finding new uses for existing therapies that already have cleared several key steps along the development path. Learn more about New Therapeutic Uses.

Templates for Success: Speeding Public-Private Partnerships

NCATS is speeding the formation of innovative private-public partnerships through the use of standardized legal agreements.

Crystal McKnight examines a compound source plate.

NCATS Funding Available to Repurpose Existing Drugs

Interested in identifying new treatments for a broad range of diseases using partially developed therapeutic candidates? Access two new funding opportunities.

NCATS Funds Drug Repurposing Projects, Seeks New Industry Partners

NCATS is seeking additional industry partners to participate in future New Therapeutic Uses funding opportunities.

About New Therapeutic Uses

Read more about the New Therapeutic Uses program and its progress.

New Therapeutic Uses Funding Information

Find out how to apply for New Therapeutic Uses funding.

Assets & Agreements for NIH-Industry Partnerships

Partner with New Therapeutic Uses

Learn how to partner with New Therapeutic Uses.

New Therapeutic Uses Projects

Find details about ongoing New Therapeutic Uses projects.

About New Therapeutic Uses

Read more about the New Therapeutic Uses program and its progress.

New Therapeutic Uses Funding Information

Find out how to apply for New Therapeutic Uses funding.

Assets & Agreements for NIH-Industry Partnerships

Partner with New Therapeutic Uses

Learn how to partner with New Therapeutic Uses.

New Therapeutic Uses Projects

Find details about ongoing New Therapeutic Uses projects.

Work with Us

Learn more about how you can access funding and collaborate with the New Therapeutic Uses program.

Bobbie Ann Mount, Ph.D.

New Therapeutic Uses Facts

Therapeutic development is a costly, complex and time consuming process. The average length of time from target discovery to approval of a new drug is about 14 years. The failure rate during this process exceeds 95 percent, and the cost per successful drug can be $1 billion or more. The high therapeutic development failure rate means there are many existing, partially developed therapeutic candidates that could be repurposed for use in new disease indications.Learn more about the New Therapeutic Uses program through the fact sheet (PDF - 395KB).

NCATS Programs & Initiatives

3-D Tissue Bioprinting Program

A Specialized Platform for Innovative Research Exploration

Assay Development and Screening Technology

Assay Guidance Manual

Biomedical Data Translator

Bridging Interventional Development Gaps

Chemistry Technology

Clinical and Translational Science Awards Program

Discovering New Therapeutic Uses for Existing Molecules

Genetic and Rare Diseases Information Center

Matrix Combination Screening

NCATS Chemical Genomics Center

NCATS' Role in the NIH HEAL Initiative^SM

NCATS Toolkit for Patient-Focused Therapy Development

NIH Common Fund Programs

Pfizer's Centers for Therapeutic Innovation

Rare Diseases Registry Program

Rare Diseases Clinical Research Network

Trans-NIH RNAi Facility

Small Business Innovation Research & Small Business Technology Transfer

Therapeutics for Rare and Neglected Diseases

Tissue Chip for Drug Screening

Toxicology in the 21st Century

Access NCATS Expertise & Resources

NCATS Programs & Initiatives